Renalytix Plc (LON:RENX – Get Free Report)’s stock price traded down 3.2% during mid-day trading on Thursday . The stock traded as low as GBX 7.20 ($0.09) and last traded at GBX 7.50 ($0.09). 194,880 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 433,320 shares. The stock had previously closed at GBX 7.75 ($0.10).
Renalytix Stock Performance
The company has a debt-to-equity ratio of 173.95, a quick ratio of 2.42 and a current ratio of 0.53. The company has a fifty day moving average of GBX 8.15 and a two-hundred day moving average of GBX 12.84. The firm has a market capitalization of £12.32 million, a price-to-earnings ratio of -30.94 and a beta of 2.10.
Insider Buying and Selling
In related news, insider Christopher H. B. Mills sold 83,696 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of GBX 8 ($0.10), for a total value of £6,695.68 ($8,393.73). 35.74% of the stock is currently owned by company insiders.
About Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.
Read More
- Five stocks we like better than Renalytix
- Ride Out The Recession With These Dividend Kings
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- 3 Ways To Invest In Coffee, Other Than Drinking It
- MarketBeat Week in Review – 11/18 – 11/22
- What is a SEC Filing?
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.